All News

2018

October

Media Release / Oct 19, 2018

Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC

Read More
Media Release / Oct 18, 2018

Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth

Read More

September

Media Release / Sep 24, 2018

Novartis announces five grant recipients of eXcellence in Ophthalmology Vision Award (XOVA) for nonprofit sustainable eye health initiatives

Read More

July

Media Release / Jul 23, 2018

Novartis renews drug donation of Egaten® (triclabendazole) until 2022, reaffirming its commitment to the fight against liver fluke

Read More
Media Release / Jul 18, 2018

Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company

Read More

June

Media Release / Jun 29, 2018

Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn

Read More
Media Release / Jun 15, 2018

Novartis study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer

Read More
Media Release / Jun 15, 2018

Sandoz presents new long-term and switching data for biosimilars Zessly® (infliximab) and Erelzi® (etanercept) in rheumatoid arthritis

Read More

May

Media Release / May 24, 2018

Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseases

Read More
Media Release / May 17, 2018

Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer

Read More

Pages

Related Links

Annual Report 2017

Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.

Learn More